No results for ‘’
Supriya Lifescience Ltd
NSE: SUPRIYA BSE: 543434
₹932.20
(0.01%)
Wed, 24 Jun 2026, 05:02 pm
Market Cap (in Cr)7493.75
PE Ratio35.88
Dividend0.11
Health Technology
Pharmaceuticals: Major
24.5KCompany History
2008
- The Company was incorporated upon its conversion from a partnership firm to a public limited company.
- The Company commenced operations.
2009
- Production of Ketamine Hydrochloride started.
2010
- CEP (Certificate of Sustainability) was granted for Chlorphenamine Maleate.
2011
- IDL was granted for Chlorphenamine Maleate.
2013
- COFEPRIS and KFDA approval was granted.
2014
- USFDA approval was granted.
- IDL was granted for Brompheniramine Maleate.
2015
- EUGMP and EDQM approval was granted.
2017
- CEP (Certificate of Sustainability) was granted for Pheniramine Maleate.
- Second time USFDA approval was granted.
2018
- CEP (Certificate of Sustainability) was granted for Brompheniramine Maleate, Mepyramine Maleate and Ketamine Hydrochloride.
2020
- Third time USFDA approval was granted.
2021
- CEP (Certificate of Suitability) was granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate.
- NMPA approval was granted.
- Health Canada approval was granted.
2022
- Supriya Lifescience Limited signed a captive solar project agreement with Enrich Energy Pvt. Ltd.
2024
- Supriya Lifescience Ltd inaugurated a state-of-the-art Module E production block at Lote Parshuram, Maharashtra.
- Supriya Lifescience inaugurated a Rs 125 crore API production block at Lote Parshuram site.